Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $10.16 Analyst target: $22.32 Upside: 119.69%
Hyperliquid Strategies Inc., through its subsidiary, is a a biotechnology company that owns a platform for biologic medicines of single or bifunctional action. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.